Background
Phase III RCT (APACT). 866 patients with resected pancreatic ductal adenocarcinoma randomized 1:1 to adjuvant nab-paclitaxel + gemcitabine versus gemcitabine alone for six 28-day cycles. Primary endpoint was independently assessed disease-free survival (DFS).
Interventions and follow up
Arm A: nab-Paclitaxel 125 mg/m² + gemcitabine 1,000 mg/m² days 1, 8, 15 every 28 days ×6 cycles
Arm B: Gemcitabine 1,000 mg/m² days 1, 8, 15 every 28 days ×6 cycles
Primary endpoint: Independently assessed disease-free survival
Median follow-up: 63.2 months (5-year analysis)
Arm B: Gemcitabine 1,000 mg/m² days 1, 8, 15 every 28 days ×6 cycles
Primary endpoint: Independently assessed disease-free survival
Median follow-up: 63.2 months (5-year analysis)
Results
Independent DFS: 19.4 vs 18.8 months, HR 0.88, P=.18 — primary endpoint NOT met
Investigator-assessed DFS: 16.6 vs 13.7 months, HR 0.82, P=.02
mOS (5-yr cutoff): 41.8 vs 37.7 months, HR 0.80, P=.0091
Investigator-assessed DFS: 16.6 vs 13.7 months, HR 0.82, P=.02
mOS (5-yr cutoff): 41.8 vs 37.7 months, HR 0.80, P=.0091
Adverse events
Overall: Grade ≥3 treatment-emergent AEs 86% vs 68%; two treatment-related deaths per arm.
Neurologic/hematologic: Grade ≥3 peripheral neuropathy 12% vs 0%; grade ≥3 neutropenia 38% vs 27%.
Neurologic/hematologic: Grade ≥3 peripheral neuropathy 12% vs 0%; grade ≥3 neutropenia 38% vs 27%.
Conclusions
APACT did not meet its primary endpoint of independently assessed DFS (HR 0.88, P=.18) despite a statistically significant 5-year OS benefit (HR 0.80, P=.0091). Discordance between independent and investigator DFS assessments complicated interpretation. nab-Paclitaxel + gemcitabine is not approved as adjuvant therapy based on the primary endpoint failure.
Key Limitations
The regulatory-grade primary endpoint (independent DFS) was not met. Discordance between independent and investigator-assessed DFS introduces methodological uncertainty. Substantially higher toxicity (86% grade ≥3) without confirmed DFS benefit makes the risk-benefit unfavorable. An OS benefit without a DFS benefit is biologically unusual and may reflect informative censoring or post-progression treatment imbalances. mFOLFIRINOX (PRODIGE-24) is clearly superior to gemcitabine alone in fit patients with better regulatory standing.
Clinical Context
APACT did not earn FDA approval in the adjuvant setting. nab-Paclitaxel + gemcitabine is approved for metastatic pancreatic cancer (MPACT) but failed to translate to the adjuvant setting. Current adjuvant standards (per ESMO/ASCO) remain mFOLFIRINOX (PRODIGE-24) and gemcitabine ± capecitabine (ESPAC-4).
References
References: Tempero MA et al, J Clin Oncol 2023 (APACT)